Interim analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (MBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIS)

This article has no abstract
Epistemonikos ID: 87d30e0e00630bf003e962096e1589a7fc98cc43
First added on: Feb 12, 2025